Smith & Nephew gains after report it may evaluate a break-up

Smith & Nephew gains after report it may evaluate a break-up
Smith & Nephew investors may push for breakup - Mail on Sunday
Smith & Nephew shares surge as activist Cevian Capital reveals 5% stake
London Markets: Hargreaves Lansdown shares slump, while Smith & Nephew soar as U.K. stocks grapple with geopolitics
11.45BUSD
Type
Common Stock
Exchange
PINK
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
GB0009223206
CUSIP
-
Sector
Healthcare
Industry
Medical Devices
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
20.14
PEG Ratio
1.08
Book Value
6.23
Dividend Share
0.391
Dividend Yield
2.89%
Earnings Share
0.72
Wall Street Target Price
48.00
EPS Estimate Current Year
-
EPS Estimate Next Year
-
EPS Estimate Current Quarter
0
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
6,163,999,744
Gross Profit TTM
4,207,000,064
EBITDA
1,336,000,000
Profit Margin
10.14%
Return On Assets TTM
5.27%
Return On Equity TTM
11.84%
Revenue Per Share TTM
7.11
Qtly Revenue Growth YOY
7.40%
Diluted Eps TTM
0.72
Qtly Earnings Growth YOY
70.40%
Trailing PE
20.14
Forward PE
12
Price Sales TTM
1.9902
Price Book MRQ
2.1666
Enterprise Value Revenue
2
Enterprise Value EBITDA
10
63.80
5.21%45.68
3.05%90.27
2.78%39.95
2.07%80.55
1.61%86.95
1.25%307.32
0.86%26.61
-1.37%19.64
-0.30%69.00
-0.10%